Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by Royce & Associates LP

Royce & Associates LP increased its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 27.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 588,178 shares of the company’s stock after acquiring an additional 127,025 shares during the period. Royce & Associates LP owned approximately 0.32% of Xeris Biopharma worth $5,623,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. GK Wealth Management LLC acquired a new position in Xeris Biopharma during the third quarter worth $32,000. Allworth Financial LP purchased a new stake in Xeris Biopharma during the second quarter worth $34,000. KBC Group NV purchased a new stake in Xeris Biopharma during the first quarter worth $27,000. William Mack & Associates Inc. acquired a new stake in Xeris Biopharma in the third quarter valued at $53,000. Finally, Sterling Capital Management LLC grew its holdings in Xeris Biopharma by 848.0% in the third quarter. Sterling Capital Management LLC now owns 5,707 shares of the company’s stock valued at $55,000 after purchasing an additional 5,105 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Insider Activity

In related news, insider Beth Hecht sold 25,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $255,750.00. Following the sale, the insider owned 1,086,130 shares of the company’s stock, valued at $11,111,109.90. This trade represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $12.49, for a total value of $312,250.00. Following the sale, the insider owned 1,559,208 shares of the company’s stock, valued at approximately $19,474,507.92. This represents a 1.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 168,332 shares of company stock worth $1,678,971 over the last three months. 4.35% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on XERS. HC Wainwright lifted their price target on Xeris Biopharma from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, November 4th. Barclays increased their price objective on shares of Xeris Biopharma from $14.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, November 11th. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 7th. Finally, Piper Sandler restated a “neutral” rating and set a $12.00 target price (up from $8.00) on shares of Xeris Biopharma in a research report on Friday, November 6th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.00.

View Our Latest Report on Xeris Biopharma

Xeris Biopharma Price Performance

XERS stock opened at $16.99 on Thursday. The stock’s 50 day moving average price is $10.92 and its 200 day moving average price is $7.98. The firm has a market cap of $3.10 billion, a P/E ratio of -339.73 and a beta of 0.61. The company has a debt-to-equity ratio of 3.89, a quick ratio of 1.58 and a current ratio of 2.15. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $17.28.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 147.75% and a negative net margin of 1.76%. The company had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. On average, sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post 0.15 earnings per share for the current fiscal year.

About Xeris Biopharma

(Free Report)

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.

Read More

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report).

Institutional Ownership by Quarter for Xeris Biopharma (NASDAQ:XERS)

Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.